Beating More Than Just Heart Disease
A BOLD VISION FOR HEALTHY HEARTS
For millions of people around the world, the chances of suffering from a stroke or heart attack is a looming threat – and great concern. With an estimated 19.1 million deaths from cardiovascular diseases in 2020, it’s easy to see why.1 Major behavioral risk factors such as tobacco use, unhealthy diet, physical inactivity, and harmful use of alcohol are leading causes of treatable cardiovascular diseases. However, even with the achievement of target LDL-C levels, millions of patients still have a significant and persistent risk of cardiovascular events, especially patients with elevated triglycerides.2 At Amarin, it is our mission to stop cardiovascular disease from being a leading cause of death, by providing our patients, doctors and investors with reliable CV treatment options.
The first step in better cardiometabolic health
Cardiovascular disease (CVD) is a major health problem, affecting millions of people globally. From hereditary conditions and lifestyle habits to societal and environmental contexts, our hearts face many concerns.
While a healthy lifestyle may slow down the progression of CVD, sometimes, more needs to be done. If necessary, your doctor may decide that lifestyle changes need to be augmented with other treatment options, to reduce elevated low-density lipoprotein cholesterol (LDL-C) levels.3 However, despite appropriate interventions, many patients' heart health may remain at risk.
This is why our ambition at Amarin is to be a part of the solution in addressing this important health issue. Always consult with your healthcare professional who is best placed to advise on any personal medical matters.
LEADING A NEW PARADIGM IN CARDIOVASCULAR HEALTH
The science behind the development of CVD is complex. We seek to improve the lives of people who are at risk of strokes, heart attacks and other serious CVD events. We do this by focusing on science, research, passion and global knowledge, to ensure we can stop cardiovascular disease from being a leading cause of death.
Making breakthroughs that change the world.
At Amarin, we’re committed to providing breakthrough treatments, scientific understanding and expertise.
Bold science for cardiovascular health
Learn about our approved product.
A BOLD investment in cardiometabolic health
Keeping our investors informed about our progress in helping stop cardiovascular disease from being a leading cause of death is important to us. Click here for our investor presentations, events and financial results.
- Cardiovascular Diseases (Cvds). World Health Organization, World Health Organization, https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
- Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188.